NCT06602193Phase 2Active not recruiting

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Study sponsor: Denali Therapeutics Inc. · DNLI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03Estimated
Enrollment · participants50Estimated
Source updated2026-05-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: 30 Apr 2026. After: Mar 2027.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview